Claritev (NYSE:CTEV – Get Free Report) SVP Tiffani Misencik sold 8,850 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $40.07, for a total value of $354,619.50. Following the transaction, the senior vice president owned 123,723 shares in the company, valued at $4,957,580.61. This trade represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Claritev Stock Down 0.5%
CTEV opened at $35.43 on Thursday. Claritev has a 52 week low of $11.50 and a 52 week high of $74.07. The business has a fifty day simple moving average of $30.27 and a 200-day simple moving average of $24.20. The firm has a market cap of $600.54 million, a P/E ratio of -2.08 and a beta of 0.74.
Claritev (NYSE:CTEV – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.10) by $5.51. The firm had revenue of $257.48 million during the quarter. Sell-side analysts expect that Claritev will post -15.08 earnings per share for the current year.
Hedge Funds Weigh In On Claritev
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on CTEV shares. Barclays began coverage on shares of Claritev in a research note on Friday, April 24th. They set an “overweight” rating and a $28.00 target price on the stock. Wall Street Zen upgraded shares of Claritev from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Canaccord Genuity Group upped their price objective on Claritev from $37.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Citigroup reiterated a “buy” rating and issued a $45.00 price objective (up from $40.00) on shares of Claritev in a research note on Monday, August 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Claritev in a report on Wednesday, June 24th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.83.
View Our Latest Stock Analysis on CTEV
Claritev Company Profile
Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.
Featured Articles
- Five stocks we like better than Claritev
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.
